Weed (BUDZ) Change in Receivables (2018 - 2019)

Weed's (BUDZ) quarterly Change in Receivables came in at $423.0 in Q2 2019, up 11.9% quarter-over-quarter from $378.0 in Q1 2019.

Weed (BUDZ) Change in Receivables (2018 - 2019) Analysis & Trends

Weed's Change in Receivables history runs 2 years deep, the most recent figure standing at $423.0 for Q2 2019.

On a quarterly basis, Change in Receivables changed N/A year-over-year to $423.0 in Q2 2019; TTM through Mar 2020 was $423.0, a 6.02% increase from a year earlier, with the FY2019 full-year figure at $801.0, up 3714.29% from the prior year.
Change in Receivables advanced to $423.0 in Q2 2019 per BUDZ's latest filing, from $378.0 in the prior quarter.
Across five years, Change in Receivables topped out at $423.0 in Q2 2019 and bottomed at $21.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-78.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	106.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-621.82 Mn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-38.20 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	126.30 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	81.40 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Weed	3.72 Mn	3.72 Mn	-	-

Download Data